Xtandi cleared by FDA for earlier-stage prostate cancer

Already a mainstay of prostate cancer therapy, Pfizer and Astellas’ Xtandi has picked up a new approval in the US that could reinvigorate the drug, even as it approaches i

EU clears review of Xtandi in earlier-stage prostate cancer

The EMA will kick off a review of Astellas and Pfizer's prostate cancer therapy Xtandi in an earlier-stage form of the cancer, which if approved could give the product a l

Bayer bags swift OK for Nubeqa in metastatic prostate cancer

Bayer has won a key FDA approval to extend the use of its prostate cancer therapy Nubeqa, as it tries to claim market share from rival drugs and fulfil its aim of building the drug into a €

Bayer triples sales forecast for prostate cancer drug Nubeqa

Bayer now says it expects to make €3 billion in sales for its prostate cancer treatment Nubeqa, up from an earlier estimate of €1 billion, after reviewing new data for the drug in metastati

Trial closes gap between Bayer's Nubeqa and rivals in prosta...

Bayer's Nubeqa is making headway as a treatment for castration-resistant prostate cancer (CRPC), but could be on track to expand its eligible patient population thanks to new phase 3 data.<

Xtandi takes fight to prostate cancer rivals with survival d...